Drug intelligence / Profile preview

INMUNO-K

Development stage: Preclinical
Lead developer: Laboratorios Farmalan
Modality: Small Molecules
Administration: Oral

Overview

INMUNO-K is an investigational immunomodulatory formulation based on calcifediol (25-hydroxyvitamin D3), currently under development by Laboratorios Farmalan, a subsidiary of Faes Farma. The project is focused on utilizing the immunomodulatory properties of vitamin D analogues to treat autoimmune diseases and other conditions requiring immune system modulation. By targeting the Vitamin D Receptor (VDR), the formulation aims to regulate immune responses that are typically dysregulated in autoimmune pathologies. It is part of a broader R&D effort by Faes Farma to expand the therapeutic applications of calcifediol beyond traditional bone health and vitamin D deficiency.

Other names: immunomodulatory calcifediol formulation project

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on INMUNO-K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INMUNO-K.

Explore the full profile